ALKS : Summary for Alkermes plc - Ordinary Shares - Yahoo Finance

U.S. Markets open in 6 hrs 13 mins

Alkermes plc (ALKS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
55.55-2.72 (-4.67%)
At close: 4:00 PM EST
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close58.27
Bid0.00 x
Ask0.00 x
Day's Range54.60 - 57.50
52 Week Range27.14 - 80.71
Avg. Volume1,219,204
Market Cap8.44B
PE Ratio (TTM)-32.68
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Alkermes Plc (ALKS): Are Hedge Funds Right About This Stock?
    Insider Monkey37 minutes ago

    Alkermes Plc (ALKS): Are Hedge Funds Right About This Stock?

    We at Insider Monkey have gone over 742 13F filings that hedge funds and prominent investors are required to file by the government. The 13F filings show the funds’ and investors’ portfolio positions as of September 30. In this article, we look at what those funds think of Alkermes Plc (NASDAQ:ALKS) based on that data. […]

  • Zacks Small Cap Research2 days ago

    CERC: CERC-501 Not Successful in Nicotine Withdrawal; Preparing for Phase 2/3 Study of CERC-501 in MDD

    The Clin501-201 study was a randomized, double blind, placebo controlled trial to evaluate the effects of 15 mg of CERC-501 on tobacco withdrawal and reinstatement and to assess craving, mood, and anxiety during 18 hours of abstinence in 66 heavy cigarette smokers (NCT02641028). The company had previously stated that it did not intend to continue development of CERC-501 in nicotine withdrawal regardless of the results, thus the fact that the drug was generally well tolerated is the most important data to come out of the study as the company pivots to developing CERC-501 as a treatment for major depressive disorder (MDD).

  • Zacks Small Cap Research8 days ago

    CERC: CERC-301 Fails to Show Benefit in MDD in Phase 2 Clinical Trial; Attention Now Turns to CERC-501

    The results showed that the trial failed to show efficacy on the primary endpoint for mean improvement in the Bech-6 scale, which is a subset of the Hamilton Depression Scale (HDRS-17), averaged over Days 2 and 4 post dose. While the result of the trial was disappointing, the company did report a potentially clinically meaningful effect on the Bech-6 and HDRS-17 for the 20 mg dose group on Day 2. The Phase 2 trial was a randomized, double blind, placebo controlled study evaluating the antidepressant effect of 12 mg and 20 mg doses of CERC-301 in MDD patients currently experiencing a severe depressive episode despite stable ongoing treatment with either an SSRI or SNRI (NCT02459236).